查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363062

美國口服固態藥物合約製造市場規模、佔有率和趨勢分析報告：2023-2030 年按產品類型、機制、最終用途和細分市場分類的趨勢

U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

美國口服固態藥物合約製造市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計2023年至2030年美國口服固態藥物合約製造市場將以6.1%的年複合成長率成長，到2030年將達到164.2億美元。

市場的成長得益於國內醫藥外包增加和技術進步等要素。隨著時間的推移，對以患者為中心的劑型的需求不斷增加，並已成為醫療領域的重要趨勢，因為它提高了用藥依從性。因此，製造商生產的口服劑型優先考慮易於吞嚥。

為了使固態口服藥物更方便使用，藥物贊助商正在創新地將藥物轉變為微片、迷你片和噴灑膠囊。這種配方方法越來越受歡迎，尤其是在兒童和老年人中。慢性病和感染疾病的日益普及也是推動新療法需求的主要要素之一。此外，不斷成長的老年人口導致慢性病罹患率上升，進一步推動了對新型治療方法的需求。

現有藥物的副作用也增加了對新治療方法的需求。例如，利物浦大學在 2022 年 7 月發表的一項研究發現，與副作用相關的住院率從 2004 年的 6.5% 增加到 2019 年的 16.5%。現有治療方法產生副作用的病例數量不斷增加，預計將推動未來對新治療方法的需求。

對許多生物製藥公司來說，創新和臨床速度是關鍵因素。小型公司和專業生物製藥公司越來越依賴滿足其行業內的這些關鍵要求。許多 CRO 和 CDMO 都標榜自己是一站式服務公司。一站式服務模式意味著CRO負責處理從原料藥到劑型、早期開發到商業化的所有事務。為了提供此類服務，CDMO 需要擁有廣泛的實行技術和專門的回應能力來解決特定問題。

此外，主要企業加大策略措施的配合措施預計也將促進美國口服固體製劑（OSD）合約製造市場的成長。例如，2023年1月，Catalent和Ethicann合作使用Catalent的口溶錠（ODT）技術Zydis開發Ethicann的臨床藥物管道。另一個例子，2023 年 3 月，Lonza 宣布其 Visp 工廠的一條新的臨床和商業藥品生產線全面運作。此次擴張預計將加強該公司的製藥服務（DPS）。

美國口服固態製劑合約製造市場報告亮點

  • 依產品類型分類，錠劑部門在 2022 年佔據最高市場佔有率。這是由於錠劑的普及、易於製造以及患者的高接受度。
  • 預計未來幾年膠囊市場將出現顯著成長。將多種藥理成分配製到具有不同釋放特性的膠囊中的可能性推動了他們的需求。
  • 從機制來看，控制釋放型在2022年佔據市場主導地位。控制釋放機制具有多種益處，包括提高功效和安全性、減少給藥頻率和穩定的血液濃度。
  • 從最終用途來看，大型企業細分市場將在 2022 年佔據主導地位。合約製造商通常有能力根據不斷變化的需求增加或減少產量。這種彈性對於 OSD 產品需求波動的大型製藥企業來說是有利的。
  • 未來年度，中小企業（SME）預計將以顯著的速度成長。中小企業的財務資源往往有限。建造和運作自家公司的製造工廠可能太昂貴。透過合約製造，您無需大量初始投資即可獲得最先進的生產能力。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 美國口服固態製劑合約製造市場：變數、趨勢、範圍

  • 市場體系預測
  • 美國口服固體製劑合約製造動態
  • 市場動態
  • 美國口服固態藥物合約製造市場：分析工具
  • 新型冠狀病毒感染疾病（COVID-19）的影響
  • 美國以吸塑包裝和瓶裝分類的口服固體製劑製劑包裝類型分析（銷售百分比，2022 年）
  • 法規狀況

第4章 美國口服固態合約製造市場：產品類型分析

  • 美國口服固態製劑合約製造市場按產品類型細分：要點
  • 美國口服固態藥物合約製造市場：產品類型變化分析
  • 依產品類型

第5章 美國口服固態藥物合約製造市場：機制分析

  • 美國口服固態製劑合約製造市場的細分市場機制：要點
  • 美國口服固態藥物合約製造市場：機制波動分析
  • 按機理

第6章 美國口服固態製劑合約製造市場：最終用戶分析

  • 美國口服固態製劑合約製造市場（按最終用戶細分）：要點
  • 美國口服固態藥物合約製造市場：最終用戶波動分析
  • 按最終用途

第7章 估計與趨勢分析

  • 美國
    • 主要國家趨勢
    • 競爭場景

第8章 競爭形勢

  • 公司分類
  • 服務熱圖分析
  • 2022年美國口服固態藥物合約生產企業市場佔有率分析
  • 公司簡介
    • Catalent, Inc.
    • Lonza
    • AbbVie Inc.
    • Aenova Group
    • Adare Pharma Solutions
    • Boehringer Ingelheim International GmbH
    • Jubilant Pharmova Limited
    • Patheon Pharma Services
    • Recipharm AB.
    • Corden Pharma International
    • Siegfried Holding AG
Product Code: GVR-4-68040-122-8

U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The U.S. oral solid dosage contract manufacturing market size is estimated to reach USD 16.42 billion by 2030, expanding at a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is attributed to factors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.

To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel treatment processes.

Adverse drug reactions to existing drugs are also contributing to the demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 to 16.5% in 2019. A rise in the number of cases involving adverse drug reactions to existing therapies is expected to boost the demand for new therapies in the future.

For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities to address specific problem statements.

Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's orally disintegrating tablet (ODT) technology 'Zydis'. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected to strengthen the company's Drug Product Services (DPS) offering.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights:

  • Based on product type, the tablets segment captured the highest market share in 2022.This is attributed to their widespread use, ease of manufacturing, and strong patient acceptance rate
  • The capsule segment is expected to show significant market growth in the coming years. Multiple pharmacological ingredients with various release characteristics can be combined in capsules, thus driving their demand
  • Based on the mechanism, the controlled release segment dominated the market in 2022. The controlled release mechanism offers multiple advantages, such as improved efficacy and safety, reduced dosage frequency, and steady blood levels
  • Based on the end-user, the large companies segment dominated the market in 2022. Contract manufacturers generally have the capacity to scale production up or down based on requirement fluctuation. This flexibility can be advantageous for large pharma companies that experience varying levels of demand for their OSD products
  • Medium- and small-sized companies are expected to advance at a significant growth rate in the coming years. Financial resources are frequently limited for small- and medium-sized companies. Their own manufacturing facilities might be too expensive to build and operate. They can gain cutting-edge production capabilities through contract manufacturing without making a large initial investment

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates And Forecast Timeline.
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information/data Analysis
    • 1.4.1 Information Analysis
  • 1.5 Market Formulation & Visualization
  • 1.6 Data Validation & Publishing
  • 1.7 Market Definitions/scope
  • 1.8 Model Details
    • 1.8.1 Approach 1: Parent Market Analysis
    • 1.8.2 Approach 2: Service/ Commodity Flow Analysis
    • 1.8.3 Approach 3: Value-chain-based Sizing & Forecasting
    • 1.8.4 Approach 4: Qfd Model Sizing & Forecasting
  • 1.9 Market Formulation & Validation
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Primary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 U.S. Oral Solid Dosage Contract Manufacturing Dynamics
  • 3.3 Market Dynamics
    • 3.3.1 Market Driver Impact Analysis
    • 3.3.2 Market Restraint Analysis
  • 3.4 U.S. Oral Solid Dosage Contract Manufacturing Market: Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 PESTEL Analysis
  • 3.5 COVID-19 Impact
    • 3.5.1 Activities by Market Players
    • 3.5.2 Long-Term Changes in The Pharmaceutical Contract Manufacturing Market
  • 3.6 Analysis Pertaining to Oral Solid Dosage Packaging Types in the U.S. by Blisters vs. Bottles (Volume % Share, 2022)
    • 3.6.1 Blister Packaging
    • 3.6.2 Bottle Packaging
    • 3.6.3 Types of Blister Packaging
      • 3.6.3.1 Blister Packaging
  • 3.7 Regulatory Landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Rest Of The World

Chapter 4 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Analysis

  • 4.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Product Type Segment: Key Takeaways
  • 4.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Movement Analysis
  • 4.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Product Type (USD Million)
    • 4.3.1 Tablets
      • 4.3.1.1 Tablets Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.2 Capsules
      • 4.3.2.1 Capsules Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.3 Powders
      • 4.3.3.1 Powders Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.4 Granules
      • 4.3.4.1 Granules Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.5 Others
      • 4.3.5.1 Others Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Analysis

  • 5.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Mechanism Segment: Key Takeaways
  • 5.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Movement Analysis
  • 5.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Mechanism (USD Million)
    • 5.3.1 Immediate Release
      • 5.3.1.1 Immediate Release Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 5.3.2 Delayed Release
      • 5.3.2.1 Delayed Release Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 5.3.3 Controlled Release
      • 5.3.3.1 Controlled Release Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Analysis

  • 6.1 U.S. Oral Solid Dosage Contract Manufacturing Market by End-user Segment: Key Takeaways
  • 6.2 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Movement Analysis
  • 6.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by End User (USD Million)
    • 6.3.1 Large-Size Companies
      • 6.3.1.1 Large-Size Companies Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 6.3.2 Medium & Small-Size Companies
      • 6.3.2.1 Medium & Small Size Companies Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 6.3.3 Others
      • 6.3.3.1 Others Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 7 Country Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 7.1 U.S.
    • 7.1.1 Key Country Dynamics
    • 7.1.2 Competitive Scenario
      • 7.1.2.1 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Service Heat Map Analysis
  • 8.3 U.S. Oral Solid Dosage Contract Manufacturing Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Catalent, Inc.
      • 8.4.1.1 Participants' Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product/Service Benchmarking
      • 8.4.1.4 Strategy Initiatives
    • 8.4.2 Lonza
      • 8.4.2.1 Participants' Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product/Service Benchmarking
      • 8.4.2.4 Strategy Initiatives
    • 8.4.3 AbbVie Inc.
      • 8.4.3.1 Participants' Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product/Service Benchmarking
      • 8.4.3.4 Strategy Initiatives
    • 8.4.4 Aenova Group
      • 8.4.4.1 Participants' Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product/Service Benchmarking
      • 8.4.4.4 Strategy Initiatives
    • 8.4.5 Adare Pharma Solutions
    • 8.4.6 Boehringer Ingelheim International GmbH
    • 8.4.7 Jubilant Pharmova Limited
    • 8.4.8 Patheon Pharma Services
    • 8.4.9 Recipharm AB.
    • 8.4.10 Corden Pharma International
    • 8.4.11 Siegfried Holding AG

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Oral Solid Dosage Contract Manufacturing Market by Product Type, 2018 - 2030 (USD Million)
  • Table 4 U.S. Oral Solid Dosage Contract Manufacturing Market by Mechanism, 2018 - 2030 (USD Million)
  • Table 5 U.S. Oral Solid Dosage Contract Manufacturing Market by End User, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. oral solid dosage contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation and Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 Parent market analysis
  • Fig. 9 Service/Commodity Flow Analysis
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD model sizing & forecasting
  • Fig. 12 Market formulation & validation
  • Fig. 13 Market snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Segment snapshot
  • Fig. 16 Competitive landscape snapshot
  • Fig. 17 Parent market outlook, 2022 (USD Million)
  • Fig. 18 Ancillary market outlook, 2022 (USD Million)
  • Fig. 19 U.S. oral solid dosage contract manufacturing market dynamics
  • Fig. 20 Biosimilar approval in the U.S. and EU per year (2016 - 2021)
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 U.S. oral solid dosage contract manufacturing market: PESTEL analysis
  • Fig. 23 Oral solid dosage packaging types in the U.S., 2022 (volume percentage share %)
  • Fig. 24 Oral solid dosage blister packaging types in the U.S., 2022 (volume percentage share %)
  • Fig. 25 Regulatory Landscape
  • Fig. 26 U.S. oral solid dosage contract manufacturing market: Product type outlook and key takeaways
  • Fig. 27 U.S. oral solid dosage contract manufacturing market: Product type movement analysis
  • Fig. 28 U.S. tablets contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 U. S. capsules contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 U. S. powders contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. granules contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 U. S. others contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. oral solid dosage contract manufacturing market: mechanism outlook and key takeaways
  • Fig. 34 U.S. oral solid dosage contract manufacturing market: mechanism movement analysis
  • Fig. 35 U.S. immediate release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. delayed release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. controlled release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. oral solid dosage contract manufacturing market: end-user outlook and key takeaways
  • Fig. 39 U.S. oral solid dosage contract manufacturing market: End-user movement analysis
  • Fig. 40 Large-Size Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Medium & small size companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 U.S. oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key company categorization
  • Fig. 46 Service heat map analysis
  • Fig. 47 U.S. oral solid dosage contract manufacturing market share analysis, 2022